Axithra logo — Rapid Therapeutic Drug Monitoring

Axithra

Rapid Therapeutic Drug Monitoring

Founded 2023 Belgium Belgium 21 employees Seed Total: $10.00M Biotechnology, Health Care

General Information

Company Name Axithra
Founded Year 2023
Location Belgium Belgium
Employees 21
Industries Biotechnology, Health Care
Funding Stage Seed
Business Model B2B, B2D, SaaS
Revenue Model Usage Based, Service Fee, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Axithra. To contact Axithra, visit axithra.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Axithra compare?

A PDF of Axithra and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Axithra soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Axithra

Axithra, established in 2023, is a novel biotechnology venture originating as a spin-off from Ghent University and imec in Belgium. The company is advancing the field of healthcare with its platform designed for Rapid Therapeutic Drug Monitoring.

Axithra's flagship technology employs proprietary optical and photonics systems to precisely track and measure drug concentrations in the bloodstream. This innovation empowers physicians to offer personalized treatment, beginning with a focus on fine-tuning beta-lactam antibiotics for ICU patients. Such precision could significantly elevate patient care by tailoring therapies to individual needs in real-time.

The startup recently secured a €10.00M seed investment on 01 September 2023. The funding round was led by a consortium of investors, including Kurma Partners, Imec.xpand, Noshaq, QBIC, WE Venture, Hamamatsu Iwata Shinkin Bank, White Fund, Werfen, and Wallonie Entreprendre.

Business keywords: Therapeutic Drug Monitoring, Personalized Medicine, Beta-lactam Antibiotics, Intensive Care Unit, Drug Concentration Measurement, Optical Technology, Photonics Technology, Platform Development, Healthcare Innovation, Patient Care Optimization, Proprietary Technology, Spin-off Startup

Services & Products

Rapid therapeutic drug monitoring
Active drug fraction measurement
Multi-drug quantification

Target Customers

Healthcare professionals Intensive care units Clinical laboratories Hospital pharmacists

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed €10.00M 9
Kurma Partners, Imec.xpand +7
01 Sep 2023
Spinout Undisclosed 2
imec, Ghent University
01 Jan 2023

Axithra Alternatives & Competitors

View All Alternatives
Axithra vs

Innovative therapeutic procedures for Intensive Care Medicine for the treatment of severe infections...

17 employees
Biotechnology, Health Care
Axithra vs
Resuscitec
Resuscitec Germany

Life is our mission

Series B
61 employees
Biotechnology, Health Care
Axithra vs
GlucoSet
GlucoSet Norway

Intensive care monitoring

16 employees
Biotechnology, Health Care

FAQ About Axithra

Rapid Therapeutic Drug Monitoring
Axithra was founded in 2023.
Axithra is headquartered in Belgium.
Axithra operates in Biotechnology and Health Care. Its work centres on Therapeutic Drug Monitoring, Personalized Medicine, Beta-lactam Antibiotics and Intensive Care Unit. Its customers include Healthcare professionals, Intensive care units and Clinical laboratories.
Axithra has a B2B, B2D and SaaS business model. Its revenue comes from Usage Based, Service Fee and Product Sales.
Axithra has approximately 21 employees.
Axithra has completed 2 funding rounds, raising a total of $10.00M. The latest funding stage is Seed.
Axithra offers: Rapid therapeutic drug monitoring, Active drug fraction measurement, Multi-drug quantification.
Top alternatives and competitors to Axithra include ARTCLINE GmbH, Resuscitec, GlucoSet, Entia, AEON Global Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Axithra and ARTCLINE GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Axithra, https://bouncewatch.com/company/axithra, updated 7 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes